Method and apparatus for non-invasively monitoring plasma glucose levels

• US 5,036,861 A
• Filed: 01/11/1990
• Issued: 08/06/1991
• Est. Priority Date: 01/11/1990
• Status: Expired due to Fees

• Current Assignee: Carter R. Anderson, Sembrowich, Walter L., William R. Kennedy
• Original Assignee: Carter R. Anderson, Sembrowich, Walter L., William R. Kennedy
• Inventors: Anderson, Carter R., Kennedy, William R., Sembrowich, Walter L.
• Primary Examiner(s): Hindenburg, Max
• Application Number:
  US07/463,387
• Time in Patent Office: 572 Days
• Field of Search: 128/632, 128/760, 128/771, 604/20, 604/312
• US Class Current: 600/573
• CPC Class Codes: A61B 5/14521 using means for promoting sweat production, e.g. heating the skin measuring sweat secretion A61B5/4266
• CPC Class Codes: A61B 5/14532 for measuring glucose, e.g. by tissue impedance measurement
• CPC Class Codes: A61B 5/4266 sweat secretion
• CPC Class Codes: A61N 1/325 for iontophoresis, i.e. transfer of media in ionic state by an electromotoric force into the body electrodes for external use A61N1/0428
• CPC Class Codes: G01N 33/66 involving blood sugars, e.g. galactose

Abstract

A method and apparatus non-invasively monitor plasma constituent levels. A localized, modified sweating response is induced providing a sweat secretion for analysis of the plasma constituents.

Claims

1. A method of non-invasively monitoring a constituent in the plasma of a patient, the method comprising:

non-invasively inducing a localized sweating response;

non-invasively introducing an agent causing the constituent to appear in sweat secretions;

collecting a discrete sample of pharmacologically-induced sweat, containing the constituent, at a skin surface; and

monitoring a characteristic of the constituent in the sample.

2. The method of claim 1 wherein non-invasively inducing a localized sweating response includes heating a localized area of skin.

3. The method of claim 1 wherein non-invasively inducing a localized sweating response includes mobilizing a first pharmacologic agent transdermally via medical iontophoresis.

4. The method of claim 3 wherein the first pharmacologic agent is a cholinergic agent.

5. The method of claim 1 wherein the constituent is glucose.

6. The method of claim 5 wherein the step of non-invasively introducing an agent causing the constituent to appear in sweat secretions further comprises the step of:

non-invasively introducing a pharmacologic agent which blocks glucose reabsorption from sweat.

7. The method of claim 6 and further comprising the step of:

non-invasively introducing a pharmacologic agent which provides an energy supply for secreting sweat glands.

8. The method of claim 7 wherein the pharmacologic agent which blocks glucose reabsorption includes phlorizin and the pharmacologic agent which provides an energy supply includes glucose-6-phosphate.

9. A method for non-invasively monitoring plasma glucose levels in a patient, the method comprising:

non-invasively inducing a localized sweating response, introducing a first pharmacologic agent which blocks glucose reabsorption by the sweat gland, and introducing a second pharmacologic agent non-invasively which provides an energy supply for the secreting sweat gland;

collecting a discrete sample of pharmacologically-modified sweat, containing glucose, at the surface of the skin; and

determining a plasma glucose level based upon the glucose contained in the sample.

10. The method of claim 9 wherein non-invasively inducing a localized sweating response includes heating a localized area of the skin.

11. The method of claim 9 wherein non-invasively inducing a localized sweating response includes mobilizing a third pharmacologic agent transdermally via medical iontophoresis.

13. The method of claim 9 and wherein non-invasively introducing the first and second pharmacologic agents includes transdermally mobilizing the agents via medical iontophoresis.

14. The method of claim 9 and wherein the first agent which blocks glucose reabsorption includes phlorizin.

15. The method of claim 9 and wherein the second agent which provides an energy supply includes glucose-6-phosphate.

12. The method of claim wherein the third pharmacologic agent is a cholinergic agent.

16. A method of non-invasively monitoring a concentration of a constituent in plasma of a patient, the method comprising:

stimulating sweat secretion in a localized area of the patient'"'"'s body;

modifying sweat gland secretion in the localized area so that a concentration of the constituent in sweat secreted in the localized area has a known relationship to the concentration of the constituent in the plasma; and

measuring concentration of the constituent in a sample of sweat secreted in the localized area.

17. The method of claim 16 wherein stimulating sweat secretion comprises heating a localized area of the skin.

18. The method of claim 16 wherein stimulating sweat secretion comprises introducing transdermally a first pharmacologic agent which induces a localized sweating response.

19. The method of claim 18 wherein the first pharmacologic agent includes pilocarpine.

20. The method of claim 16 wherein modifying sweat gland secretion comprises introducing transdermally a second pharmacologic agent which blocks glucose reabsorption from sweat.

21. The method of claim 20 wherein the constituent is glucose.

22. The method of claim 20 wherein the second pharmacologic agent includes phlorizin.

23. The method of claim 20 wherein introducing an agent further comprises introducing transdermally a third pharmacologic agent which provides an energy supply for secreting sweat glands.

24. The method of claim 23 wherein the third pharmacologic agent includes glucose-6-phosphate.

25. The method of claim 16 wherein measuring concentration comprises:

collecting a sample of sweat secreted in the localized area; and

measuring concentration of the constituent in the sample collected.

26. An apparatus for non-invasively monitoring a constituent in the plasma of a patient, comprising:

an inducer for non-invasively inducing a localized sweating response;

a modifier for non-invasively modifying the sweating response to make the constituent appear in sweat secretions;

a collector for collecting a discrete sample of pharmacologically-induced sweat, containing the constituent, at a skin surface; and

a monitor for monitoring a characteristic of the constituent in the sample.

27. The apparatus of claim 26 wherein the inducer comprises:

a heater for heating a localized area of skin.

28. The apparatus of claim 26 wherein the inducer comprises:

a mobilizer for mobilizing a first pharmacologic agent transdermally via medical iontophoresis.

29. The apparatus of claim 28 wherein the first pharmacologic agent is a cholinergic agent.

30. The apparatus of claim 26 wherein the constituent is glucose.

31. The apparatus of claim 30 and further comprising:

a first introducer for non-invasively introducing a second pharmacologic agent which blocks glucose reabsorption from sweat.

32. The apparatus of claim 31 and further comprising:

a second introducer for non-invasively introducing a third pharmacologic agent which provides an energy supply for secreting sweat glands.

33. The apparatus of claim 32 wherein the second pharmacologic agent comprises:

phlorizin and the third pharmacologic agent comprises glucose-6-phosphate.

34. An apparatus for non-invasively monitoring plasma glucose levels in a patient, comprising:

an inducer for non-invasively inducing a localized sweating response, introducing a first pharmacologic agent non-invasively which blocks glucose reabsorption by the sweat gland, and for introducing a second pharmacologic agent non-invasively which provides an energy supply for the secreting sweat gland.

35. The apparatus of claim 34 and further comprising:

a collector for collecting a discrete sample of pharmacologically-modified sweat, containing glucose, at the surface of the skin.

36. The apparatus of claim 35 and further comprising:

a glucose level determining device for determining a plasma glucose level based upon the glucose combined in the sample.

37. The apparatus of claim 34 wherein the inducer comprises a heater for heating a localized area of the skin.

38. The apparatus of claim 34 wherein the inducer comprises:

a mobilizer for mobilizing a third pharmacologic agent transdermally via medical iontophoresis.

39. The apparatus of claim 38 wherein the third pharmacologic agent is a cholinergic agent.

40. The apparatus of claim 34 wherein the first and second pharmacologic agents are introduced by transdermally mobilizing the agent via medical iontophoresis.

41. The apparatus of claim 34 wherein the first agent which blocks glucose reabsorption includes phlorizin.

42. The apparatus of claim 34 wherein the second pharmacologic agent which provides an energy supply includes glucose-6-phosphate.

43. An apparatus for non-invasively monitoring a concentration of a constituent in plasma of a patient, comprising:

an stimulator for stimulating sweat secretion in a localized area of patient'"'"'s body; and

a modifier for modifying sweat gland secretion in the localized area so that a concentration of the constituent in sweat secreted in the localized area has a known relationship to the concentration of the constituent in the plasma.

44. The apparatus of claim 43 and further comprising:

a measurement device for measuring concentration of the constituent in a sample of sweat secreted in the localized area.

45. The apparatus of claim 44 wherein the measurement device comprises:

a collector for collecting a sample of sweat secreted in the localized area; and

a measuring device for measuring concentration of the constituent in the sample collected.

46. The apparatus of claim 43 wherein the stimulator comprises:

a heater for heating a localized area of the skin.

47. The apparatus of claim 43 wherein the stimulator comprises:

a transdermal introducer for transdermally introducing a fist pharmacologic agent which induces a localized sweating response.

48. The apparatus of claim 47 wherein the first pharmacologic agent includes pilocarpine.

49. The apparatus of claim 43 wherein the modifier comprises:

a transdermal introducer for transdermally introducing a second pharmacologic agent which blocks glucose reabsorption from sweat.

50. The apparatus of claim 49 wherein the constituent is glucose.

51. The apparatus of claim 48 wherein the second pharmacologic agent includes phlorizin.

52. The apparatus of claim 49 wherein the transdermal introducer comprises a second transdermal introducer for introducing transdermally a third pharmacologic agent which provides an energy supply for secreting sweat glands.

53. The apparatus of claim 51 wherein the third pharmacologic agent includes glucose-6-phosphate.